Electrophysiological effects of brompheniramine on cardiac ion channels and action potential

Pharmacological Research

Volumn 54, Issue 6, 2006, Pages 414-420

  Shin, Won Ho ^a   Kim, Ki Suk ^a   Kim, Eun Joo ^a  

^a Korea Institute of Toxicology   (South Korea)

Author keywords

Action potential; Antihistamine; Brompheniramine; hERG; QT interval prolongation

Indexed keywords

BROMPHENIRAMINE; ION CHANNEL; POTASSIUM CHANNEL HERG; SODIUM CHANNEL;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; HEART ELECTROPHYSIOLOGY; HEART PAPILLARY MUSCLE; IC 50; MALE; MICROELECTRODE; MUSCLE CELL; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; REPOLARIZATION;

ACTION POTENTIALS; ANIMALS; BROMPHENIRAMINE; CALCIUM CHANNELS; GUINEA PIGS; HEART; HISTAMINE H1 ANTAGONISTS; ION CHANNELS; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; PAPILLARY MUSCLES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNELS;

EID: 33846030799     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.08.004     Document Type: Article

References (24)

1. Craft T.M. Tosade de pointes after astemizole overdose. Br Med J (Clin Res Ed) 292 (1986) 660
2. Snook J., Boothman-Burrell D., Watkins J., and Colin-Jones D. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 42 (1988) 257-259
3. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., and Cantilena Jr. L.R. Torsades de pointes occurring in association with terfenadine use. JAMA 264 (1990) 2788-2790
4. MacConnell T.J., and Stanners A.J. Torsades de pointes complicating treatment with terfenadine. BMJ 302 (1991) 1469
5. Ben-David J., and Zipes D.P. Torsades de pointes and proarrhythmia. Lancet 341 (1993) 1578-1582
6. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
7. Sanguinetti M.C. Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann N Y Acad Sci 868 (1999) 406-413
8. Roy M., Dumaine R., and Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94 (1996) 817-823
9. Vorperian V.R., Zhou Z., Mohammad S., Hoon T.J., Studenik C., and January C.T. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28 (1996) 1556-1561
10. Wang W.X., Ebert S.N., Liu X.K., Chen Y.W., Drici M.D., and Woosley R.L. "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol 32 (1998) 123-128
11. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., and Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43 (2004) 369-379
12. Authority of the Board of Directors of the American Society of Health-System Pharmacists. AHFS drug information, Maryland: American Society of Health-System Pharmacists, Inc.; 2002, p. 10.
13. Vaughan E.M., and Williams D.M. Classification of antidysrhythmic drugs. Pharmacol Ther [B] 1 (1975) 115-138
14. Yatani A., and Brown A.M. The calcium channel blocker nitrendipine blocks sodium channels in neonatal rat cardiac myocytes. Circ Res 56 (1985) 868-875
15. Bou-Abboud E., and Nattel S. Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug-induced sodium channel blockade by sodium bicarbonate. Circulation 94 (1996) 1954-1961
16. Wasserstrom J.A., and Salata J.J. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. Am J Physiol 254 (1988) H1157-H1166
17. max as a measure of the sodium current in cardiac and nervous tissues. Biophys J 23 (1978) 147-152
18. Chiang C.E., Luk H.N., Wang T.M., and Ding P.Y. Effects of sildenafil on cardiac repolarization. Cardiovasc Res 55 (2002) 290-299
19. Guth B.D., Germeyer S., Kolb W., and Markert M. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Meth 49 (2004) 159-169
20. Tanaka H., Masumiya H., Kato Y., and Shigenobu K. Inhibitory effects of terfenadine on the rising phase of action potentials and sinus rates in isolated guinea-pig myocardium. Gen Pharmacol 27 (1996) 337-340
21. Gintant G.A., Limberis J.T., McDermott J.S., Wegner C.D., and Cox B.F. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37 (2001) 607-618
22. Shin W.H., and Kim E.J. The different effects of phenothiazines on cardiac action potential duration. Basic Clin Pharmacol Toxicol 96 (2005) 143-145
23. Hayashi S., Kii Y., Tabo M., Fukuda H., Itoh T., Shimosato T., et al. QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci 99 (2005) 423-437
24. Witchel H.J., Hancox J.C., and Nutt D.J. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 23 (2003) 58-77